2Michel B. Angiotensin Ⅱ type Ⅰ receptor blockers. Circulation ,2001,103 : 904-912.
3Meredith PA. Optimal dosing characteristics of the angiotensin Ⅱ receptor antagonist temisartan. Am J Cardiol, 1999 , 84:7-12.
4Elliott Wj. Circadian variation in the timing of stroke onset : a meta-analysis. Stroke, 1998,29:992-996.
二级参考文献5
1Guidelines.Subcommittee of the World Health Organization-International Society of Hypertension(WHO/ISH) Mild Hypertension Liason Committee.1999 World Health Organization-International.Society of Hypertension guidelines for the management of hypertension.J Hypertens,1999,17(2):151-183
2Devereux RB,Alonso DR,Lutas EM,et al.Echocardiographic assessment of left ventricular hypertrophy:comparison to necropsy findings[J].Am J Cardiol,1986,57(6):450-458
3Criscione L,De Gasparo M,Buhlmayer P,et al.Pharmaclogical profile of valsartan:a potent,orally active,nonpeptide antagonist of thangiotensin Ⅱ AT1 receptor subtype.Br J Pharmacol,1993,110(2):761-771
